New book by Larry Connors Click here Improve your trading - See how
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
Fidaxomicin abstracts and speakers include:
"Low Recurrence Rate among Patients with C. difficile Infection (CDI)
Treated with Fidaxomicin (FDX)"
Poster Presentation: Yoav Golan, M.D., M.S.
Monday, September 14, 2009 11:15am-1:15pm Pacific Time
Presentation number: L1-1639 in Hall B
"Restriction Endonuclease Analysis (REA) Typing of Clostridium difficile
in a Phase 3 Treatment Trial of Fidaxomicin vs Vancomycin: Decreased Cure
Rate for Epidemic BI/NAP1/027 Strain"
Poster Presentation: Dale N. Gerding, M.D.
Monday, September 14, 2009 11:15am-1:15pm Pacific Time
Presentation number: L1-1642 in Hall B
"Comparative Fidaxomicin Susceptibilities of Isolates Collected at
Baseline, Failure, and Recurrence from Patients in a Phase III Trial of
Clostridium difficile Infection (CDI)"
Poster Presentation: Ellie J. Goldstein, M.D.
Monday, September 14, 2009 11:15am-1:15pm Pacific Time
Presentation number: L1-1641 in Hall B
"Safety of Fidaxomicin Versus Vancomycin in Treatment of Clostridium
difficile Infection"
Poster Presentation: Sherwood L. Gorbach, M.D.
Monday, September 14, 2009 11:15am-1:15pm Pacific Time
Presentation number: L1-1640 in Hall B
"Pharmacokinetics/Pharmacodynamics (PK/PD) of Fidaxomicin in Treatment of
Clostridium difficile Infection (CDI)"
Poster Presentation: Pam Sears, Ph.D.
Tuesday, September 15, 2009 9:00am-11:00am Pacific Time
Presentation number: A1-1949 in Hall D
"Rifampin, Rifaximin, OPT-80 and Tigecycline Susceptibility of C.
difficile Strains from Canada and Italy: Rifamycin Resistance Entirely
Predicted by Rifampin E-test with Divergent Rifamycin Resistance among the
Two Countries"
Poster Presentation: Mark A. Miller, M.D.
Tuesday, September 15, 2009 9:00am-11:00am Pacific Time
Presentation number: C2-1958 in Hall D
"Acquisition and Overgrowth of Vancomycin-Resistant Enterococci in
Patients Treated with Fidaxomicin (FDX) Versus Vancomycin (VAN) for
Clostridium difficile Infection"
Oral Presentation: Curtis J. Donskey, M.D.
Tuesday, September 15, 2009 10:45am-11:00am Pacific Time
Presentation number: K-1915 in Room 131
Prulifloxacin abstracts and speakers include:
"Prulifloxacin, a New Fluoroquinolone Treatment for Traveler's Diarrhea"
Poster Presentation: Prof. Robert Steffen, M.D.
Monday, September 14, 2009 11:15am-1:15pm Pacific Time
Presentation number: L1-1643 in Hall B
"Recommended Ulifloxacin (Prulifloxacin) MIC Quality Control Ranges for
Campylobacter jejuni ATCC 33560 Using a CLSI Multi-Laboratory M23-A3 Study
Design"
Poster Presentation: J.M. Streit
Monday, September 14, 2009 11:15am-1:15pm Pacific Time
Presentation number: D-1433 in Hall B
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Contacts
Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736
Porter Novelli Life Sciences
Jason I. Spark, Vice President
619-849-6005
SOURCE Optimer Pharmaceuticals, Inc.
http://www.optimerpharma.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.